Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Ogier

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology in Drug Development|February 4, 2025
Bioavailability, Metabolism, and Excretion of [<sup>14</sup>C]-Tazemetostat in Patients With B-Cell Lymphomas or Advanced Solid TumorsYingxue Chen, Renli Teng, Julien Ogier
Future Medicinal Chemistry|March 24, 2011
Recent advances in the field of nanometric drug carriersJulien Ogier, Thomas Arnauld, Eric Doris
European Journal of Drug Metabolism and Pharmacokinetics|October 7, 2023
The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy ParticipantsRose Marino, Louise Dube, Julien Ogier, et al.
Organic & Biomolecular Chemistry|August 27, 2009
Poly-6-cationic amphiphilic cyclodextrins designed for gene deliveryColin Byrne, Florence Sallas, Dilip K Rai, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 6, 2011
Drug delivery and imaging with polydiacetylene micellesEdmond Gravel, Julien Ogier, Thomas Arnauld, et al.
Plos One|June 28, 2013
Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna DeliveryAoife M O'Mahony, Julien Ogier, Raphael Darcy, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 21, 2023
A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese ParticipantsLouise Dube, Nobuhiko Haga, Donna Grogan, et al.
Clinical Pharmacology in Drug Development|May 10, 2025
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced MalignanciesYingxue Chen, Renli Teng, Attila Szanto, et al.
Organic & Biomolecular Chemistry|May 23, 2012
A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA deliveryAoife M O'Mahony, Julien Ogier, Stephane Desgranges, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology in Drug Development|February 4, 2025
Bioavailability, Metabolism, and Excretion of [<sup>14</sup>C]-Tazemetostat in Patients With B-Cell Lymphomas or Advanced Solid TumorsYingxue Chen, Renli Teng, Julien Ogier
Future Medicinal Chemistry|March 24, 2011
Recent advances in the field of nanometric drug carriersJulien Ogier, Thomas Arnauld, Eric Doris
European Journal of Drug Metabolism and Pharmacokinetics|October 7, 2023
The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy ParticipantsRose Marino, Louise Dube, Julien Ogier, et al.
Organic & Biomolecular Chemistry|August 27, 2009
Poly-6-cationic amphiphilic cyclodextrins designed for gene deliveryColin Byrne, Florence Sallas, Dilip K Rai, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|December 6, 2011
Drug delivery and imaging with polydiacetylene micellesEdmond Gravel, Julien Ogier, Thomas Arnauld, et al.
Plos One|June 28, 2013
Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna DeliveryAoife M O'Mahony, Julien Ogier, Raphael Darcy, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 21, 2023
A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese ParticipantsLouise Dube, Nobuhiko Haga, Donna Grogan, et al.
Clinical Pharmacology in Drug Development|May 10, 2025
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced MalignanciesYingxue Chen, Renli Teng, Attila Szanto, et al.
Organic & Biomolecular Chemistry|May 23, 2012
A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA deliveryAoife M O'Mahony, Julien Ogier, Stephane Desgranges, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
Pageof 2